What’s the latest?
Several customers have recently provided updates about their aseptic filling projects.
ADMA Biologics CEO Adam Grossman said the following after the completion of a site acceptance test for their SA25 Aseptic Filling Workcell: “We believe the SA25 is an easy-to-use, all-in-one solution for our in-house aseptic filling requirements and will allow ADMA to bring our products to patients faster, improve our margins, as well as substantially increase our end-to-end control over our manufacturing process.”
FUJIFILM Diosynth Biotechnologies installed a second SA25 at their College Station, TX site–this one for the manufacturing of recombinant proteins.
Dr. Chris Chen, the CEO of CDMO WuXi Biologics said the following after successful pre-filled syringe production for clients. WuXi Biologics said in the same update that they had 50 filling projects booked on the machine. “Featuring modularization, robotic automation and a closed system, this state-of-the-art line reflects our leadership in biologics manufacturing innovation. DP4 has demonstrated our diverse aseptic filling capabilities, maintaining high product quality and extensive flexibility to serve the complex biologics filling needs of our clients.”
As a result of the company’s continued rapid growth, we are hiring a significant amount of people. There are several available roles in bioprocessing and controls engineering and manufacturing. See the careers page for more details.